|
Reducing Non-Core Trial Procedures Could Save Billions: Tufts Researcher
Drugmakers are paying anywhere from $3 billion to $5 billion annually for clinical trial procedures that may not be necessary, a new study concludes.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives